NANBIOSIS took part in the 2026 ICTS Conference in Zaragoza, bringing together Spain’s leading scientific infrastructures to exchange knowledge and explore collaboration opportunities.
Zaragoza, October 2026 — Last 29 October 2026, the V Annual Conference of Spain’s Singular Scientific and Technical Infrastructures (ICTS) took place in Zaragoza, bringing together representatives from across the Spanish ICTS network. The event provided a forum to share developments, strengthen collaboration between infrastructures and showcase their scientific and technological capabilities to the research and industrial communities.
This year’s conference was hosted by the Laboratory of Advanced Microscopy (LMA) and the Institute for Biocomputation and Physics of Complex Systems (BIFI), both at the University of Zaragoza. Sessions were held at the Agustín de Betancourt Building, home to the University’s School of Engineering and Architecture (EINA).
The programme included two round tables addressing key challenges for research infrastructures: artificial intelligence in ICTS and data management plans (DMPs). These discussions provided an opportunity to exchange perspectives on the role of emerging technologies and effective data management in the development and operation of large-scale scientific facilities.
Participants also had the opportunity to visit the LMA facilities and the Aragonese node of the Spanish Supercomputing Network (RES), alongside the conference’s networking activities.
The event scenified a minute of silence in memory of the victims of the Urda train accident. In addition, participants who were unable to attend in person were offered the possibility of joining the sessions by videoconference.
Through its participation, NANBIOSIS reaffirmed its commitment to the Spanish ICTS network, contributing to a shared effort to promote scientific excellence, facilitate access to advanced research infrastructures and foster collaboration across the national research and innovation ecosystem.
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
If you want to collaborate with us, visit our Order Request page.
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:
